Redefining Ovarian Cancer Care with Biomarkers

Labcorp, Rebecca Previs, Kyle Strickland, ovarian cancer, diagnosis, biomarker, HRD, RB1, tumor biology

Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology.

Sep 7^th • 14 mins listen

Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing

Quest Diagnostics, Jesus Izaguirre Carbonell, Thoman Slavin, MRD testing, minimal residual testing, precision tool, biomarker, ctDNA, circulating tumor DNA

Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions.

Jul 7^th • 19 mins listen

Tumor-Agnostic Therapies and the Future of HER2 in Oncology

Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen

Rethinking How We Track and Treat Cancer

Labcorp, Rebecca Previs, Michelle Green, genomics, ASCO, HER2, HER3, MRD, breast cancer, antibody drug conjugate, ADC, breast cancer, lung cancer, ctDNA, biomarker

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Jul 13^th • 19 mins listen

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Highlights From Today’s Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we’re learning that any given tumor may harbor a variety of variants. So, if we’re considering using in situ hybridization (ISH)…

Mar 30^th • 47 mins listen